X. L. Xu

426 citations

19 papers · 324 indexed · h-index 7

Rheumatology
- Rheumatoid Arthritis Research and Therapies 8
- Spondyloarthritis Studies and Treatments 5
Molecular Biology
- DNA Repair Mechanisms 1
Immunology
- Psoriasis: Treatment and Pathogenesis 7
- Biosimilars and Bioanalytical Methods 2
Hematology
Cell Biology
Pediatrics, Perinatology and Child Health
- Pharmaceutical studies and practices 4
Pathology and Forensic Medicine
- Autoimmune Bullous Skin Diseases 3
Epidemiology
- Influenza Virus Research Studies 1

Co-authors: G. Lynn Law Vivian L. MacKay David Morris Kyle Serikawa Eileen Turcott David R. Goodlett Mark R. Flory Lue Ping Zhao
Cited by: Rheumatology Molecular Biology Immunology
Journals: Annals of the Rheumatic Diseases (13 papers)Cell Host & Microbe (1 paper)Journal of General Virology (1 paper)
Partner nations: United States United Kingdom Canada

In The Last Decade

X. L. Xu

19 papers receiving 317 citations

Peers

Countries citing papers authored by X. L. Xu

Since Specialization

Citations

This map shows the geographic impact of X. L. Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by X. L. Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites X. L. Xu more than expected).

Fields of papers citing papers by X. L. Xu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by X. L. Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by X. L. Xu. The network helps show where X. L. Xu may publish in the future.

Co-authorship network

The 25 scholars most cited alongside X. L. Xu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with X. L. Xu Line = papers co-authored together X. L. Xu links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work
1	Identification of a broad-inhibition influenza neuraminidase antibody from pre-existing memory B cells Cell Host & Microbe ·Xin Wang,Huihui Kong,Bingxin Chu,Qian Yang,Chaohui Lin,Rui Liu,Changxu Chen,Yang Gao,guojun wang,Dayan Wang,Qin Chen,Xiaohua Ye,Lifei Yu,X. L. Xu,J. Jin,Ren Sun,Hualan Chen,Xudong Wu,Zeli Zhang	2024	4
2	AB0892 Targeted Safety Analyses of Guselkumab: Long-Term Results from Randomized Clinical Trials in Patients with Active Psoriatic Arthritis and Moderate to Severe Psoriasis Annals of the Rheumatic Diseases ·Philip J. Mease,P. Foley,Karin Reich,S. D. Chakravarty,M. Shawi,Ya‐Wen Yang,Megan Miller,Alexa P. Kollmeier,X. L. Xu,Jingxue Yu,Y. Wang,S. Sheng,Yin You,Iain B. McInnes	2022	1
3	POS1070 BASELINE DETERMINANTS OF PAIN RESPONSE IN PATIENTS WITH PSORIATIC ARTHRITIS RECEIVING GUSELKUMAB Annals of the Rheumatic Diseases ·Peter Nash,Christopher T. Ritchlin,Proton Rahman,M. Shawi,E. Rampakakis,Y. Lee,Alexa P. Kollmeier,X. L. Xu,J. Sherlock,Daniel Cua,Saakshi Khattri,Enrique R. Soriano,D. Mcgonagle	2022	1
4	POS1035 LOW RATES OF RADIOGRAPHIC PROGRESSION WITH 2 YEARS OF GUSELKUMAB, A SELECTIVE INHIBITOR OF THE INTERLEUKIN-23p19 SUBUNIT: RESULTS FROM A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF BIOLOGIC-NAÏVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS Annals of the Rheumatic Diseases ·Philip J. Mease,A.B. Gottlieb,Iain B. McInnes,Proton Rahman,Alexa P. Kollmeier,X. L. Xu,Y. Jiang,S. Sheng,M. Shawi,Soumya D. Chakravarty,F. Lavie,D. van der Heijde	2022	1
5	POS1017 GUSELKUMAB PROVIDES CONTINUED IMPROVEMENT IN KEY DOMAINS OF PSORIATIC ARTHRITIS THROUGH 2 YEARS Annals of the Rheumatic Diseases ·Laura C. Coates,L. Gossec,Christine Contré,M. Shawi,E. Rampakakis,N. Shiff,Alexa P. Kollmeier,X. L. Xu,Peter Nash,Philip J. Mease,Philip Helliwell	2022	1
6	POS0195 GUSELKUMAB TREATMENT MODULATES CORE PSORIATIC ARTHRITIS GENE EXPRESSION IN TWO PHASE 3 CLINICAL TRIALS (DISCOVER-1 AND -2) Annals of the Rheumatic Diseases ·Stefan Siebert,Kristen Sweet,Christopher T. Ritchlin,Elizabeth C. Hsia,Alexa P. Kollmeier,X. L. Xu,Qingxuan Song,María Luisa Limón Mirón	2021	4
7	POS1027 EFFICACY AND SAFETY OF GUSELKUMAB, A MONOCLONAL ANTIBODY SPECIFIC TO THE p19-SUBUNIT OF INTERLEUKIN-23, THROUGH 2 YEARS: RESULTS FROM A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY CONDUCTED IN BIOLOGIC-NAÏVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS Annals of the Rheumatic Diseases ·Iain B. McInnes,Proton Rahman,A.B. Gottlieb,E. C. Hsia,Alexa P. Kollmeier,X. L. Xu,S. Sheng,Y. Jiang,M. Shawi,Soumya D. Chakravarty,D. van der Heijde,Philip J. Mease	2021	3
8	AB0528 COMPARABLE SAFETY PROFILE OF GUSELKUMAB IN PSORIATIC ARTHRITIS AND PSORIASIS: RESULTS FROM PHASE 3 TRIALS THROUGH 1 YEAR Annals of the Rheumatic Diseases ·Alice B. Gottlieb,Joseph F. Merola,April W. Armstrong,Richard G. Langley,Mark Lebwohl,C.E.M. Griffiths,M. Shawi,Ya‐Wen Yang,E. C. Hsia,Alexa P. Kollmeier,X. L. Xu,Miku Izutsu,P. Ramachandran,S. Sheng,Yin You,Megan Miller,Christopher T. Ritchlin,Iain B. McInnes,Proton Rahman	2021	1
9	FRI0359 INTEGRATED SAFETY RESULTS OF TWO PHASE-3 TRIALS OF GUSELKUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS THROUGH THE PLACEBO-CONTROLLED PERIODS Annals of the Rheumatic Diseases ·Proton Rahman,Christopher T. Ritchlin,Philip Helliwell,Wolf‐Henning Boehncke,P. J. Mease,Alice B. Gottlieb,Shelly Kafka,Alexa P. Kollmeier,Elizabeth C. Hsia,X. L. Xu,M. Shawi,S. Sheng,Prasheen Agarwal,B. Zhou,Padmakumar Ramachandran,Iain B. McInnes	2020	1
10	SAT0402 EFFICACY AND SAFETY OF GUSELKUMAB, A MONOCLONAL ANTIBODY SPECIFIC TO THE P19-SUBUNIT OF INTERLEUKIN-23, THROUGH WEEK 52 OF A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY CONDUCTED IN BIOLOGIC-NAÏVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS Annals of the Rheumatic Diseases ·Iain B. McInnes,Proton Rahman,Alice B. Gottlieb,Elizabeth C. Hsia,Alexa P. Kollmeier,X. L. Xu,Ramanand A. Subramanian,Prasheen Agarwal,S. Sheng,Y. Jiang,Bei Zhou,D. van der Heijde,Philip J. Mease	2020	2
11	AB0801 EFFECTS OF GUSELKUMAB, A MONOCLONAL ANTIBODY THAT SPECIFICALLY BINDS TO THE P19-SUBUNIT OF INTERLEUKIN-23, ON DACTYLITIS AND ENTHESITIS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: POOLED RESULTS THROUGH WEEK 24 FROM TWO PHASE 3 STUDIES Annals of the Rheumatic Diseases ·Dennis McGonagle,Iain B. McInnes,Atul Deodhar,G. Schett,Philip J. Mease,M. Shawi,Shelly Kafka,Chetan S. Karyekar,Alexa P. Kollmeier,Elizabeth C. Hsia,X. L. Xu,S. Sheng,Prasheen Agarwal,Bei Zhou,Christopher T. Ritchlin,Proton Rahman	2020	2
12	OP0054 EFFICACY OF GUSELKUMAB, A MONOCLONAL ANTIBODY THAT SPECIFICALLY BINDS TO THE P19-SUBUNIT OF IL-23, ON ENDPOINTS RELATED TO AXIAL INVOLVEMENT IN PATIENTS WITH ACTIVE PSA WITH IMAGING-CONFIRMED SACROILIITIS: WEEK-24 RESULTS FROM TWO PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES Annals of the Rheumatic Diseases ·Philip Helliwell,Dafna D. Gladman,Denis Poddubnyy,Philip J. Mease,Xenofon Baraliakos,Alexa P. Kollmeier,Elizabeth C. Hsia,X. L. Xu,S. Sheng,Prasheen Agarwal,B. Zhou,S. D. Chakravarty,M. Shawi,Chetan S. Karyekar,Atul Deodhar,Désirée van der Heijde	2020	12
13	SAT0397 GUSELKUMAB, AN IL-23 INHIBITOR THAT SPECIFICALLY BINDS TO THE IL23P19-SUBUNIT, FOR ACTIVE PSORIATIC ARTHRITIS: ONE YEAR RESULTS OF A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF PATIENTS WHO WERE BIOLOGIC-NAÏVE OR TNFΑ INHIBITOR-EXPERIENCED Annals of the Rheumatic Diseases ·Christopher T. Ritchlin,Philip Helliwell,Wolf‐Henning Boehncke,E. C. Hsia,Alexa P. Kollmeier,Ramanand A. Subramanian,X. L. Xu,S. Sheng,Y. Jiang,B. Zhou,Atul Deodhar	2020	1
14	Phase 2a, randomized, double‐blind, placebo‐controlled, multicentre, parallel‐group study of an H₄R‐antagonist (JNJ‐39758979) in adults with uncontrolled asthma Clinical & Experimental Allergy ·Alexa P. Kollmeier,Andrew Greenspan,X. L. Xu,Philip E. Silkoff,Elliot S. Barnathan,Matthew J. Loza,Joel Jiang,Bei Zhou,B. Chen,Robin L. Thurmond	2018	10
15	OP0308 Efficacy and safety results of guselkumab in patients with active psoriatic arthritis over 56 weeks from a phase 2a, randomised, double-blind, placebo-controlled study Annals of the Rheumatic Diseases ·Atul Deodhar,Alice B. Gottlieb,Wolf‐Henning Boehncke,Bo Dong,Y. Wang,Yanli Zhuang,William Barchuk,X. L. Xu,Elizabeth C. Hsia	2018	9
16	Responder analysis and correlation of outcome measures: pooled results from two identical studies comparing etoricoxib, celecoxib, and placebo in osteoarthritis Osteoarthritis and Cartilage ·Clifton O. Bingham,Steve Bird,Steven S. Smugar,X. L. Xu,Andrew M. Tershakovec	2008	25
17	Gene Expression Analyzed by High-resolution State Array Analysis and Quantitative Proteomics Molecular & Cellular Proteomics ·Vivian L. MacKay,Xiaohong Li,Mark R. Flory,Eileen Turcott,G. Lynn Law,Kyle Serikawa,X. L. Xu,Hookeun Lee,David R. Goodlett,Ruedi Aebersold,Lue Ping Zhao,David Morris	2004	149
18	Inactivation of human SRBC, located within the 11p15.5-p15.4 tumor suppressor region, in breast and lung cancers. PubMed ·X. L. Xu,Leeju C. Wu,Feng Du,Alan R. Davis,Michael Peyton,Yoshio Tomizawa,A. Maitra,Gail E. Tomlinson,A F Gazdar,Bernard E. Weissman,A. Bowcock,Richard Baer,John D. Minna	2001	87
19	A modified hepatitis B virus surface antigen with the receptor-binding site for hepatocytes at its C terminus: expression, antigenicity and immunogenicity Journal of General Virology ·X. L. Xu,Guideng Li,Yu Kong,Hongru Yang,Zhiyuan Zhang,Huidong Cao,Yuqin Wang	1994	10

About X. L. Xu

X. L. Xu is a scholar working on Rheumatology, Immunology and Pediatrics, Perinatology and Child Health, having authored 19 papers that have together received 324 indexed citations. Recurring topics across this work include Rheumatoid Arthritis Research and Therapies (8 papers), Psoriasis: Treatment and Pathogenesis (7 papers), Spondyloarthritis Studies and Treatments (5 papers), Pharmaceutical studies and practices (4 papers), Autoimmune Bullous Skin Diseases (3 papers), Biosimilars and Bioanalytical Methods (2 papers), Influenza Virus Research Studies (1 paper) and DNA Repair Mechanisms (1 paper). The work is most often cited by research in Rheumatology (51 citations), Molecular Biology (195 citations) and Immunology (53 citations). X. L. Xu has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include G. Lynn Law, Vivian L. MacKay, David Morris, Kyle Serikawa, Eileen Turcott, David R. Goodlett, Mark R. Flory, Lue Ping Zhao, Xiaohong Li and Hookeun Lee. Their work appears in journals such as Annals of the Rheumatic Diseases, Cell Host & Microbe and Journal of General Virology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact